Advanced liver cancer: TACE with immunotherapy and anti-angiogenesis
Part of Cancer, Digestive system clinical trials.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced hepatocellular carcinoma (HCC) that has spread outside your liver.
- You have not received any systemic therapy (like chemotherapy, targeted therapy, or immunotherapy) for your liver cancer before.
- You have had a TACE procedure (a liver tumor-blocking treatment) either within 3 months before or after starting your first dose of immunotherapy or anti-angiogenesis drugs.
- After the TACE procedure, you received at least 1 cycle of a combination therapy with an immunotherapy drug (PD-1/PD-L1 inhibitor) and an anti-angiogenesis drug (like those used for HCC).
- You have measurable tumors in your liver that can be seen on imaging.
- You do not have other types of liver cancer (such as cholangiocarcinoma, fibrolamellar, sarcomatoid, or mixed types), and you do not have severe liver impairment (Child-Pugh C) or poor performance status (PS > 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This study looks at combining TACE (a procedure that delivers chemotherapy directly to the liver) with two newer drugs — tislelizumab (immunotherapy) and lenvatinib (targeted therapy) — for people with advanced liver cancer. The goal is to see how well this combination works when used together.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.